Last updated: May 25, 2026
DaCTINOMYCIN suppliers: API and contract manufacturing landscape, key vendors, and sourcing routes
Executive summary: Suppliers of dactinomycin fall into two lanes: (1) commercial API/finished-dose supply controlled by a small number of manufacturers because the molecule is older, supply chains are tightly managed, and oncology demand is concentrated; (2) specialty/compounding and hospital distribution networks that stock injectable vials and manage cold-chain and sterile handling. Publicly available supplier lists and reseller inventories exist, but reliable, litigation-ready sourcing typically requires confirmation from the specific ANDA/NDA label holder, CMO/sterile manufacturer, and the distributor of record on the branded or generic product carton.
Who sells dactinomycin injection and where are the common supply channels?
Answer (high level): Dactinomycin is sold primarily as sterile injectable vials through brand/generic distributors that serve oncology treatment centers and hospital pharmacies. For acquisition, buyers typically use either:
- Wholesalers/distributors of record for the specific labeled NDC
- Specialty pharmaceutical distributors that handle high-acuity oncology products
- Direct purchase from licensed manufacturers for institutional volumes (usually via procurement frameworks)
What are typical product forms supplied for dactinomycin?
- Sterile lyophilized powder or solution for intravenous (IV) use depending on the marketed presentation
- Vial-based single-dose packaging intended for dilution under sterile technique
Which purchasing routes dominate institutional procurement?
- NDC-level sourcing through group purchasing organizations (GPOs), then distributor fulfillment
- Emergency supply routing through multiple wholesalers when allocation occurs
- Distributor-managed recall and lot tracking for controlled oncology injectable handling
What companies supply dactinomycin active pharmaceutical ingredient (API)?
Answer: Dactinomycin API is a narrow, specialist-supply segment. Sourcing is generally concentrated in manufacturers that produce complex antibiotics/oncology cytotoxics under GMP with validated impurity profiles and tight sterile and containment controls during manufacture and packaging.
API supply constraints that affect supplier availability
- Complex molecular handling for a cytotoxic antibiotic
- High regulatory scrutiny on impurity profile, residual solvents, and microbial controls
- Demand volatility tied to cancer treatment protocols and clinician prescribing patterns
- Contract manufacturing capacity in sterile oncology and packaging lines
How to identify the correct API supplier for a given finished product
A finished vial’s manufacturing chain often separates:
- API manufacturer (upstream)
- Finished-dose manufacturer (sterile fill-finish)
- Labeler/distributor (market authorization and commercial supply)
Procurement teams typically map suppliers by NDC labeler, then trace:
- FDA drug listing and label manufacturing/packager statements
- Inspection history tied to sterile manufacturing sites
- Lot traceability in batch documentation
What finished-dose manufacturers make dactinomycin injectable under GMP sterile conditions?
Answer: Dactinomycin injectable is typically made by companies with sterile cytotoxic fill-finish capabilities. Buyers should treat “supplier” as either:
- the finished-dose manufacturer on the label, or
- the distributor of record for the NDC they plan to buy
Sterile manufacturing risk points that affect supplier performance
- Aseptic fill-finish line readiness for cytotoxic antibiotics
- Environmental monitoring and contamination control for sterile injectables
- Validated cleaning/segregation procedures due to cytotoxic containment
- Allocation policies during line downtime
How does dactinomycin supplier selection change by country or region?
Answer: Supplier lists vary by geography because availability depends on local:
- market authorization status for the specific NDC/presentation
- distributor network coverage for oncology injectables
- licensing and labeling requirements
Common regional sourcing patterns
- US: tends to rely on FDA-approved labelers and wholesaler distribution for NDC-level purchasing
- EU/UK: typically uses centralized marketing authorization labeling and national wholesalers
- Emerging markets: more variability in distributor networks and product presentation availability
What role do distributors, wholesalers, and group purchasing organizations play in dactinomycin supply?
Answer: Distributors control day-to-day access for hospitals and oncology clinics, while wholesalers control broad accessibility across many customer accounts.
Procurement reality for oncology injectables
- Hospital purchasing often uses GPO contracts
- Non-contract supply can be accessed through specialty distributors
- Allocation events typically trigger cross-network sourcing and expedited procurement
Which suppliers are most relevant for licensing, tendering, and batch qualification?
Answer: For licensing, tenders, and qualifying alternative sources, the relevant entities are:
- the finished-dose manufacturer listed on the product label (sterile site)
- the API manufacturer named via documentation or traceability
- any CMO/packager performing sterile fill-finish or packaging
- the distributor of record for contractual supply
Qualification artifacts that buyers usually require
- CoA by lot with impurity profile and potency
- GMP certificates for the manufacturing sites
- Validation/compatibility data for dilution and IV use (label-based)
- Lot traceability and recall procedures
What generic or alternative dactinomycin product supply risks exist?
Answer: The primary risks are not “generic-to-generic” substitution risks alone, but product availability risk from limited production capacity and the complexity of sterile cytotoxic handling.
Typical risk drivers
- Sterile manufacturing line constraints
- Limited number of suppliers for API and sterile fill-finish
- Quality incidents that stop shipment while corrective actions are completed
What is the supplier due diligence checklist for dactinomycin?
Answer: Buyers should qualify suppliers at three levels: molecule quality (API), sterile product quality (finished-dose site), and commercial reliability (distributor and fulfillment).
Due diligence items
- Verify manufacturing sites and batch responsibility in documentation
- Confirm aseptic controls and cytotoxic containment procedures at sterile fill-finish
- Require lot-level CoA and test acceptance criteria
- Confirm packaging integrity, labeling accuracy, and tamper-evidence
- Validate supply continuity (lead times, allocation policy)
Key Takeaways
- Dactinomycin supply is concentrated, and buyer “supplier” should mean the NDC-level finished-dose labeler/manufacturer plus the distributor of record.
- API sourcing is a narrow lane dominated by specialist manufacturers; finished-dose sterile fill-finish is typically the operational bottleneck.
- For procurement, licensing, and qualification, map the chain: API maker → sterile fill-finish/packager → labeler/distributor using label language and lot traceability.
- Supplier reliability depends more on sterile capacity and cytotoxic handling controls than on typical commodity pharmaceutical supply dynamics.
FAQs
- How do hospitals qualify an alternate source for dactinomycin injection during allocation?
- What documents are required to validate a new dactinomycin vendor for oncology pharmacy procurement?
- Does dactinomycin supply differ for different vial presentations or label strengths?
- What is the fastest sourcing strategy when dactinomycin vials go on backorder?
- How should procurement teams handle lot traceability and recalls for dactinomycin?
References
- U.S. Food and Drug Administration (FDA). Drug Products (Orange Book, when applicable) and prescribing information databases.
- FDA. Drug Registration and Listing System (DRLS) and label/labeler information.
- FDA. Current Good Manufacturing Practice (cGMP) and sterile drug product guidance materials.
